
A recent study in Clinical Microbiology and Infection shows that patients undergoing long-term kidney replacement therapy (KRT) had significant reductions in morbidity and mortality after three doses of COVID-19 vaccine.
The study was based on all patients on KRT from the Finnish Registry for Kidney Diseases. Each patient was matched with 10 controls, and hazard ratios of hospitalizations and deaths due to COVID-19 were calculated according to vaccination status to estimate vaccine effectiveness (VE).
Overall, 5,755 KRT patients, including 2,547 on dialysis and 3,208 kidney-transplant recipients, were compared with 57,253 controls. Between January 1, 2020, and December 31, 2022, 784 (30.8%) dialysis patients, 929 (29.0%) kidney transplant recipients, and 10,702 (18.7%) controls were infected with SARS-CoV-2.
Transplant patients saw reduced death with 3 doses
Among those with 2 or 3 vaccine doses, VE against hospitalization due to COVID-19 was 47% (95% confidence interval [CI], 12% to 68%) in dialysis patients, 50% (95% CI, 26% to 66%) in kidney-transplant recipients, and 76% (95% CI, 69% to 82%) in controls.
For kidney-transplant recipients, but not dialysis patients, more than three vaccine doses reduced mortality due to COVID-19 by 62% (95% CI, 14% to 83%).
Vaccination was associated with significantly reduced hospitalisation due to COVID-19.
“Vaccination was associated with significantly reduced hospitalisation due to COVID-19 among KRT patients," the authors concluded. They said this study supports booster vaccinations in these patients.